Veeva Systems (VEEV) Stock Forecast & Price Target

Veeva Systems is positioned favorably because it is still only about 16% penetrated within a $12B+ TAM while continuing to take share in core life sciences workflows, and its Q2 results showed that demand remains broad and durable with revenue of $928.0M (+18% YoY), non-GAAP EPS of $2.35, billings up 19%, and a 44.8% operating margin. Its outlook is further strengthened by Vault CRM momentum, with 12 top-20 commitments, more than 180 customers live including five top-20s, and increasing evidence that Veeva is winning a majority of enterprise and SMB deals while competing against slower implementations and weaker execution from Salesforce. The company also has a credible long-term AI-driven growth engine through Falcon, which is already profitable from day one and is expected to automate at least 70% of manual MLR labor over five years, while management raised FY27 guidance above consensus and lifted expected non-GAAP operating income to approximately $1,640M, reinforcing the view that growth and profitability can advance together.

Veeva Systems is facing a more cautious fundamental setup than its premium market narrative suggests, because recent growth is increasingly dependent on a handful of contributors such as Crossix while newer acquisitions remain early-stage and not material this year, meaning much of the upside is pushed into future periods rather than showing up in current results. The company also appears to be absorbing margin pressure from lower services gross margins tied to T20 migration, Falcon/Vault AI investment, and roughly $80M of royalties rolling off, while management itself indicates no expected step change in margins over the next 1-2 yrs and only a gradual recovery as migrations roll off and services normalize into FY29/30. Although 2Q subscription revenue grew 16.3% y/y with operating margin steady at 44.8%, the $38M 2Q billings headwind, deal-timing volatility, and slower- than-ideal transitions in Dev Cloud and newer products imply that execution risk is rising just as the stock’s quality premium depends on sustained high growth and near-best-in-class profitability.